中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

168 records (took 0.031 seconds)

    METHODS OF CONTINUOUS CELL CULTURE
    3.
    发明申请
    METHODS OF CONTINUOUS CELL CULTURE 审中-公开

    公开(公告)号：WO2020051042A1

    公开(公告)日：2020-03-12

    申请号：PCT/US2019/048594

    申请日：2019-08-28

    Applicant: MOMENTA PHARMACEUTICALS, INC.

    Inventor： YIN, Jin ,  ZANG, Ru

    IPC: B01F3/04 ,  C12M1/00 ,  C12M1/02 ,  C12M1/04

    Abstract: The present disclosure provides, among other things, continuous culture methods for producing a cell product, e.g., a recombinant protein, e.g., a glycoprotein, e.g., an antibody agent or a fusion protein. In some instances, methods herein allow large-scale production of a recombinant protein using continuous culture methods. The present disclosure identifies and addresses a problem with current continuous cell culture techniques in that at large-scale culture of certain cells have insufficient viable cell concentrations and impaired cell viability. The present disclosure provides, in part, methods and systems for large-scale continuous culture of shear-sensitive cells.

    FCRN ANTIBODIES AND METHODS OF USE THEREOF
    8.
    发明申请
    FCRN ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
    FCRN抗体及其使用方法

    公开(公告)号：WO2018023136A1

    公开(公告)日：2018-02-01

    申请号：PCT/US2017/044765

    申请日：2017-07-31

    Applicant: MOMENTA PHARMACEUTICALS, INC.

    Inventor： LING, Leona, E. ,  ROY, Sucharita ,  WASHBURN, Nathaniel ,  KEHRY, Marilyn ,  KING, David, J. ,  MEADOR, James, III ,  MANNING, Anthony ,  HILLSON, Jan

    IPC: C07K16/28 ,  G01N33/68

    Abstract: The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

    Abstract translation: 本申请的特征在于结合人新生儿Fc受体（FcRn）的抗体。 这些抗-FcRn抗体可用于例如促进受试者中自身抗体的清除，抑制受试者中的抗原呈递，阻断免疫反应，例如阻断受试者中基于免疫复合物的免疫应答激活， 并治疗受试者的免疫性疾病（例如自身免疫性疾病）。 这些抗-FcRn抗体还可用于例如降低通过怀孕受试者胎盘的致病性抗体转运，增加妊娠受试者中的致病性抗体分解代谢，并且治疗胎儿中的抗体介导的病毒性疾病增强或 新生儿。

Patent Agency Ranking